Citigroup
LXEO icon

Citigroup’s Lexeo Therapeutics LXEO Stock Holding History

Citigroup’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$436K Buy
93,743
+80,423
+604% +$435K ﹤0.01% 3972
2026
Q1 		$76.5K Sell
13,320
-1,973
-13% -$14K ﹤0.01% 4375
2025
Q4 		$152K Buy
15,293
+7,861
+106% +$71.7K ﹤0.01% 4123
2025
Q3 		$49.3K Sell
7,432
-7,316
-50% -$35.4K ﹤0.01% 4509
2025
Q2 		$59.3K Sell
14,748
-8,579
-37% -$28.2K ﹤0.01% 4670
2025
Q1 		$80.9K Sell
23,327
-1,597
-6% -$7.08K ﹤0.01% 4706
2024
Q4 		$164K Buy
24,924
+1,819
+8% +$14.3K ﹤0.01% 4531
2024
Q3 		$209K Buy
23,105
+11,560
+100% +$138K ﹤0.01% 4315
2024
Q2 		$185K Sell
11,545
-37,632
-77% -$547K ﹤0.01% 3914
2024
Q1 		$771K Sell
49,177
-42,712
-46% -$668K ﹤0.01% 3230
2023
Q4 		$1.23M Buy
+91,889
New +$1.14M ﹤0.01% 2651

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Citigroup's LXEO Position: Q2 2026 in Review

Citigroup increased its Lexeo Therapeutics (LXEO) stake by 604% in Q2 2026, buying an estimated $435K and bringing the position to 93,743 shares worth $436K. The position accounts for ﹤0.01% of the portfolio, ranked #3972.

Citigroup first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.23M in Q4 2023. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Citigroup held 93,743 shares of Lexeo Therapeutics worth $436K as of Q2 2026.
  • Citigroup bought 80,423 Lexeo Therapeutics shares in Q2 2026, an estimated $435K.
  • Lexeo Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3972 holding.
  • Citigroup first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Citigroup's Lexeo Therapeutics position peaked at $1.23M in Q4 2023.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.